Analyst Profile

Followed by 25 followers
.
Luca Issi

Luca Issi

RBC Capital
Wall Street Analyst
#7,861 out of 8,141 Wall Street Analysts
#23,473 out of 24,284 experts

Success Rate

29%
27 out of 92 transactions made a profit

Average Return

-15.80%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Luca Issi's trades since 2021 and holding each position for 1 Year would result in 29.35% of your transactions generating a profit, with an average return of -15.8% per rating.

Stock Rating Distribution

186Ratings
55.91% Buy
44.09% Hold
0.00% Sell
Distribution of Luca Issi's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Verve Therapeutics, Inc.
(VERV)
Rating:Buy
Date:May 10, 2022 - Today
Return:+68.70%
The most profitable rating made by Luca Issi

Luca Issi's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
DRNA
Dicerna Pharma
Nov 19, 2021
Hold
Downgraded
7Ratings
80%
+31.22%
BioMarin Pharmaceutical
Oct 26, 2022
Hold
Reiterated
$95.00
(-1.98% Downside)
4Ratings
0.00%
Alnylam Pharma
Oct 27, 2022
Buy
Reiterated
$250.00
(17.53% Upside)
11Ratings
83%
+24.50%
Crispr Therapeutics AG
Nov 02, 2022
Hold
Reiterated
$70.00
(27.30% Upside)
9Ratings
0.00%
Allogene Therapeutics
Nov 02, 2022
Buy
Reiterated
$32.00
(197.12% Upside)
13Ratings
25%
-34.00%
Sangamo Biosciences
Nov 04, 2022
Buy
Reiterated
$22.00
(517.98% Upside)
7Ratings
0%
-35.67%
RegenXBio
Nov 04, 2022
Hold
Reiterated
$25.00
(10.57% Upside)
12Ratings
0.00%
Intellia Therapeutics
Nov 04, 2022
Buy
Reiterated
$140.00
(181.80% Upside)
10Ratings
0%
-28.30%
Beam Therapeutics
Nov 07, 2022
Hold
Reiterated
$60.00
(35.50% Upside)
6Ratings
0.00%
Bluebird Bio
Nov 07, 2022
Hold
Reiterated
$8.00
(5.40% Upside)
12Ratings
0.00%
List of latest recommendations made by Luca Issi. Click to expand and see Luca Issi's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >